TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9667260

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 6 for six courses, administered every 28 days
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 12 for four courses, administered every 28 days
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 12
Number of subjects: 227

Group type: COMPARATOR
Intervention: Carboplatin AUC 6
Number of subjects: 227
Study: 7853812

Group type: EXPERIMENTAL
Intervention: Serum lipoprotein spectrum evaluation in patients with cholelithiasis
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Correction of dyslipoproteinemia
Number of subjects: 63

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 63
Study: 15374499

Group type: EXPERIMENTAL
Intervention: Centrophenoxine (CPH), 2 g/day for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 50
Study: 7364818

Group type: EXPERIMENTAL
Intervention: Cephalothin
Number of subjects: 307
Study: 30426525

Group type: EXPERIMENTAL
Intervention: Hand cream dispensers equipped with an electronic system to monitor use, communicated regularly to HCWs via posters.
Number of subjects: 501

Group type: COMPARATOR
Intervention: Control group (CG) without the electronic monitoring and feedback intervention.
Number of subjects: 501
Study: 28407662

Group type: EXPERIMENTAL
Intervention: 7-day fasting program with 300 kcal/day by liquids only
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual care and dietary advice only
Number of subjects: 32
Study: 25743732

Group type: EXPERIMENTAL
Intervention: Muscle strength training program (50 minutes, twice a week for 8 weeks, including Kegel's exercise, Thera-band training, and indoor walking)
Number of subjects: 70
Study: 23531715

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HI) at 80%-90% maximal workload
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Moderate-intensity interval training (MOD) at 60%-80% maximal workload
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HI)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Moderate-intensity interval training (MOD)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (7 women)
Number of subjects: 23
Study: 22802072

Group type: EXPERIMENTAL
Intervention: STEPP program
Number of subjects: 80
Study: 19699385

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (daily dose > 1200 mg or single dose > 600 mg within 4 hours of contrast exposure)
Number of subjects: 1677

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1677
Study: 17533518

Group type: EXPERIMENTAL
Intervention: Focal expanding balloon (FB)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional unidiameter balloon (UB)
Number of subjects: 122
Study: 15211249

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid administered for 7 days
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 520
Study: 11359340

Group type: EXPERIMENTAL
Intervention: Preoperative duplex scanning
Number of subjects: 176
Study: 9874902

Group type: EXPERIMENTAL
Intervention: Child-focused cognitive-behavioral therapy (CBT)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Child-focused cognitive-behavioral therapy (CBT) plus parental anxiety management (CBT + PAM)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Child-focused cognitive-behavioral therapy (CBT + PAM)
Number of subjects: 67
Study: 7979494

Group type: EXPERIMENTAL
Intervention: Nebuhaler (750 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerochamber (140 ml)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Babyspacer (260 ml)
Number of subjects: 20
Study: 2482007

Group type: EXPERIMENTAL
Intervention: casein-predominant low protein formula
Number of subjects: 70

Group type: COMPARATOR
Intervention: humanized formula
Number of subjects: 70

Group type: COMPARATOR
Intervention: special low-birthweight formula
Number of subjects: 70
Study: 403557

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg per os)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Marihuana (10 mg delta9-THC)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol + Marihuana
Number of subjects: 6
Study: 29888541

Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI)
Number of subjects: 40
Study: 28917225

Group type: EXPERIMENTAL
Intervention: iEAT diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: modified traditional diet (control)
Number of subjects: 50
Study: 25792124

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 20170
Study: 23548443

Group type: EXPERIMENTAL
Intervention: One‐day CRM‐based classroom course
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: One‐day CRM style simulation‐based training
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Classroom training followed by simulation‐based training
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 157
Study: 21298068

Group type: EXPERIMENTAL
Intervention: Light exposure at 6500K
Number of subjects: 16

Group type: COMPARATOR
Intervention: Light exposure at 2500K
Number of subjects: 16

Group type: COMPARATOR
Intervention: Incandescent lamps at 3000K
Number of subjects: 16
Study: 19502673

Group type: EXPERIMENTAL
Intervention: Neuromobilization-based physiotherapy for two weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard physiotherapy for two weeks
Number of subjects: 108
Study: 16729207

Group type: EXPERIMENTAL
Intervention: Identification latency of 10-12 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall response latency under manipulations of retention interval and nominal lineup size
Number of subjects: 0
Study: 14705107

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation and physical therapy (SCS+PT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Physical therapy (PT)
Number of subjects: 54
Study: 12653375

Group type: EXPERIMENTAL
Intervention: 14-page patient communication workbook received 2-3 days pre-visit
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 2-page patient communication handout received in the waiting room
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 9259358

Group type: EXPERIMENTAL
Intervention: Increased dialysis volume (0.5 L per exchange, total increase of 1.5 L daily)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Unchanged dialysis regimen (4 exchanges of 2 L per day)
Number of subjects: 35
Study: 8279841

Group type: EXPERIMENTAL
Intervention: 50 mg/day of cyclophosphamide for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 mg/m2 + CDDP 75 mg/m2 every 4 weeks for 3 courses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CP therapy (cyclophosphamide 600 mg/m2 + CDDP 75 mg/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphadenectomy group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-lymphadenectomy group
Number of subjects: 0
Study: 2979681

Group type: EXPERIMENTAL
Intervention: Cimetidine, 400 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin (1300 mg, 36 mmol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control for aspirin (36 mmol HCl)
Number of subjects: 8
Study: 30348098

Group type: EXPERIMENTAL
Intervention: Fear of falling (measured by FES-I)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Physical function
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 155
Study: 27437883

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 14671

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14671
Study: 24925464

Group type: EXPERIMENTAL
Intervention: Gemcitabine with S-1 (GS)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Gemcitabine (Gem)
Number of subjects: 193
Study: 22639135

Group type: EXPERIMENTAL
Intervention: Levobupivacaine labor epidural (bolus concentration 0.25 % or less; infusion concentration 0.125 % or less)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Combined spinal‐epidural procedure (morphine 0.20 mg, fentanyl 25 µg and hyperbaric bupivacaine 2.5 mg)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Oxytocin-augmented labor
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Induced partum
Number of subjects: 144
Study: 20201992

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 417
Study: 17707079

Group type: EXPERIMENTAL
Intervention: Simultaneous intervention for PA and FI
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Sequential intervention (PA at baseline and FI at 3 months)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Sequential intervention (FI at baseline and PA at 3 months)
Number of subjects: 567

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 567
Study: 16883901

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Chemotherapy (Western group)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Combined therapy of TCM and chemotherapy (Integrative group)
Number of subjects: 294
Study: 12823702

Group type: EXPERIMENTAL
Intervention: 15% EDTAC solution
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser application (11 mm focal distance, 4 Hz frequency, 200 mJ energy, 2.25 W potency, 62 J total energy, 1 min application time)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 60
Study: 10608756

Group type: EXPERIMENTAL
Intervention: Antenatal zidovudine treatment for 2 weeks
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Antenatal zidovudine treatment
Number of subjects: 310
Study: 8857501

Group type: EXPERIMENTAL
Intervention: 16-segment model of LV segmentation
Number of subjects: 105

Group type: COMPARATOR
Intervention: 11-segment model of LV segmentation
Number of subjects: 105
Study: 1514169

Group type: EXPERIMENTAL
Intervention: Heparin (500 U heparin/h for 30 h)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control experiment
Number of subjects: 6
Study: 6370007

Group type: EXPERIMENTAL
Intervention: 15 (R)‐15‐methyl prostaglandin E2
Number of subjects: 46

Group type: COMPARATOR
Intervention: Antacid (usually Mylanta II)
Number of subjects: 46
Study: 31246661

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Promestriene (10 mg intravaginal cream 3 times a week)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vaginal lubricant application
Number of subjects: 72
Study: 29467849

Group type: EXPERIMENTAL
Intervention: IMRT combined with chemotherapy
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional radiotherapy and chemotherapy
Number of subjects: 150
Study: 26760605

Group type: COMPARATOR
Intervention: 4L PEG
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: 2L PEG plus ascorbate (PEG-A)
Number of subjects: 2802

Group type: EXPERIMENTAL
Intervention: 2L PEG with citrate and simethicone plus bisacodyl (PEG-CS)
Number of subjects: 2802
Study: 24571824

Group type: EXPERIMENTAL
Intervention: Physiotherapy rehabilitation program (Takla‐O'Donnell Protocol) including seven individual 30‐minute sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no additional physiotherapy management)
Number of subjects: 100
Study: 22954027

Group type: EXPERIMENTAL
Intervention: Early admission (within two months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual admission (after an average waiting time of eight months)
Number of subjects: 0
Study: 20051942

Group type: EXPERIMENTAL
Intervention: Double-balloon enteroscopy (DBE)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single-balloon enteroscopy (SBE)
Number of subjects: 100
Study: 17481836

Group type: EXPERIMENTAL
Intervention: Sweat patches worn for 7 days after cessation of cannabis use
Number of subjects: 11

Group type: COMPARATOR
Intervention: Oral doses of up to 14.8 mg THC/day for five consecutive days
Number of subjects: 11
Study: 15830180

Group type: EXPERIMENTAL
Intervention: High-frequency external muscle stimulation (HF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-frequency external muscle stimulation (HF) for non-painful neuropathy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for non-painful neuropathy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-frequency external muscle stimulation (HF) for painful neuropathy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS) for painful neuropathy
Number of subjects: 41
Study: 11938417

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human erythropoietin 200 U/kg/day and iron 1mg/kg/day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study: 10484096

Group type: EXPERIMENTAL
Intervention: Group II (trained twice)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Group I (trained once)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Ultrasound technician (Group III)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Overall residents
Number of subjects: 9
Study: 8567443

Group type: EXPERIMENTAL
Intervention: Pairs of clicks with interstimulus intervals under 8-9 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pairs of clicks with interstimulus intervals from 12 to 1 ms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulus alone
Number of subjects: 0
Study: 2198378

Group type: EXPERIMENTAL
Intervention: 20 mg xipamide/day
Number of subjects: 22

Group type: COMPARATOR
Intervention: 200 mg spironolactone/day combined with 40 mg of furosemide every other day
Number of subjects: 22
Study: 602716

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Decadron, 2 mg 3 times a day for 4 days)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (64 patients, no treatment mentioned)
Number of subjects: 56
Study: 30884705

Group type: EXPERIMENTAL
Intervention: Extruded sorghum
Number of subjects: 24

Group type: COMPARATOR
Intervention: Extruded wheat
Number of subjects: 24
Study: 28693983

Group type: EXPERIMENTAL
Intervention: Centrifugation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sedimentation
Number of subjects: 44
Study: 26044872

Group type: EXPERIMENTAL
Intervention: Budesonide (2 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 24379010

Group type: EXPERIMENTAL
Intervention: Olive oil-based lipid emulsion (LE)
Number of subjects: 94

Group type: COMPARATOR
Intervention: MCT/LCT emulsion-based PN
Number of subjects: 94
Study: 21564156

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivatives and synthetic bone graft (EMD/SBG)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Enamel matrix derivatives (EMD)
Number of subjects: 73
Study: 18765950

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A 0.05% (tCsA) eye drops
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (left eyes)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Treatment group (tCsA) and Control group
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Age and tCsA
Number of subjects: 31
Study: 16846555

Group type: EXPERIMENTAL
Intervention: Levalbuterol (90 microg, QID)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Racemic albuterol (180 microg)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 173

Group type: COMPARATOR
Intervention: Racemic albuterol
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Levalbuterol and racemic albuterol
Number of subjects: 173
Study: 14984495

Group type: EXPERIMENTAL
Intervention: Bolus injection (UKALL X protocol, n = 40)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Infusion (UKALL XI protocol, n = 71)
Number of subjects: 111
Study: 11242268

Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion using autografts or allografts and anterior plating
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion using anterior plating
Number of subjects: 106

Group type: COMPARATOR
Intervention: Anterior cervical decompression and fusion
Number of subjects: 106
Study: 9645886

Group type: COMPARATOR
Intervention: Initial medical therapy
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Initial surgical revascularization
Number of subjects: 686
Study: 7832572

Group type: EXPERIMENTAL
Intervention: Dynamic tests of muscle function and muscle histology
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Muscle histomorphometry
Number of subjects: 20

Group type: COMPARATOR
Intervention: Histomorphometric examination of muscle needle biopsy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactate profiles after ischaemic forearm exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Basal serum lactate levels
Number of subjects: 20

Group type: COMPARATOR
Intervention: Type II fibre atrophy factors
Number of subjects: 20
Study: 2851762

Group type: EXPERIMENTAL
Intervention: cisplatin + etoposide (DDP/VP)
Number of subjects: 150

Group type: COMPARATOR
Intervention: cyclophosphamide + etoposide (cyclo/VP)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: DDP/VP
Number of subjects: 150

Group type: COMPARATOR
Intervention: cyclo/VP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: salvage regimen with adriamycin + vindesine (ADM/VDS)
Number of subjects: 150
Study: 30428290

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg per day for 14 days, then 20 mg per day for 14 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 240
Study: 28324886

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (USS)
Number of subjects: 22966

Group type: EXPERIMENTAL
Intervention: Multimodal screening (MMS)
Number of subjects: 22966

Group type: EXPERIMENTAL
Intervention: Repeat screening (USS and MMS)
Number of subjects: 22966

Group type: EXPERIMENTAL
Intervention: Intensive screening (USS and MMS)
Number of subjects: 22966

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22966
Study: 25760973

Group type: EXPERIMENTAL
Intervention: Bevacizumab added to chemotherapy (cisplatin and paclitaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin and paclitaxel (control)
Number of subjects: 0
Study: 22153054

Group type: EXPERIMENTAL
Intervention: Computer-based simulation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Mannequin-based simulation
Number of subjects: 38
Study: 21320368

Group type: EXPERIMENTAL
Intervention: PR-S meal (solid breakfast)
Number of subjects: 15

Group type: COMPARATOR
Intervention: PR-B meal (beverage breakfast)
Number of subjects: 15
Study: 18463479

Group type: EXPERIMENTAL
Intervention: 8.3 base curve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8.6 base curve
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prototype lens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Senofilcon A lens
Number of subjects: 0
Study: 16524859

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg orally 3 times a day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12930186

Group type: EXPERIMENTAL
Intervention: Ballistic training (EXP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 38
Study: 10606839

Group type: EXPERIMENTAL
Intervention: Cimetidine 100 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9105568

Group type: EXPERIMENTAL
Intervention: E2/NETA (continuous oral 17 beta‐estradiol 2 mg/day combined with norethisterone acetate 1 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: E2/MPA (transdermal 17 beta‐estradiol 50 micrograms/day combined with cyclic medroxyprogesterone acetate 10 mg/day)
Number of subjects: 70
Study: 8407399

Group type: EXPERIMENTAL
Intervention: Adjuvant brachytherapy (BRT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: No further therapy (no BRT)
Number of subjects: 126
Study: 3084269

Group type: EXPERIMENTAL
Intervention: 20% glucose infusion for 2 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8% amino acid infusion for 2 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 0
Study: 31977921

Group type: EXPERIMENTAL
Intervention: Fireground interventions (self‐contained breathing apparatus, entry team wash down, contaminated equipment isolation, personnel showering and washing of gear)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infrared sauna treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard postfire care
Number of subjects: 0
Study: 28846163

Group type: EXPERIMENTAL
Intervention: Sonidegib 200 mg
Number of subjects: 240
Study: 27262419

Group type: EXPERIMENTAL
Intervention: 20 mg/kg IV‐TXA before skin incision (group A)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 10 mg/kg IV‐TXA 3 hours later (group B)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Two boluses of 10 mg/kg IV‐TXA at 3 and 6 hours later (group C)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Total blood loss
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: C-reactive protein and interleukin 6 levels
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Visual analog scale pain score
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Limb swelling ratio
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Hospital for Surgery Score
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Range of motion
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Length of hospital stay (LOH)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Transfusion rate
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Deep venous thrombosis
Number of subjects: 151
Study: 25722196

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg q24h for 9 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Isoniazid (300 mg q24h for 9 months)
Number of subjects: 64